Ignyta Company Profile (NASDAQ:RXDX)

Analyst Ratings

Consensus Ratings for Ignyta (NASDAQ:RXDX) (?)
Ratings Breakdown: 6 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $19.67 (263.52% upside)

Analysts' Ratings History for Ignyta (NASDAQ:RXDX)
Show:
DateFirmActionRatingPrice TargetActions
7/12/2016Credit Suisse Group AGReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/23/2016JPMorgan Chase & Co.Initiated CoverageOverweight$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/17/2016Cantor FitzgeraldReiterated RatingBuy$18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/6/2016Jefferies GroupReiterated RatingBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/8/2016Piper Jaffray Cos.Reiterated RatingBuy$32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/23/2014 forward)

Earnings

Earnings History for Ignyta (NASDAQ:RXDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/10/2016Q1($0.68)($0.79)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/14/2016Q415($0.57)($1.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($0.60)($0.49)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.65)($0.51)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115($0.79)($1.15)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/14/2015($0.79)($1.05)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/17/2015Q414($0.59)($2.18)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2014Q314$0.01($0.55)$215.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014($0.26)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014($0.37)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ignyta (NASDAQ:RXDX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.63)($0.50)($0.57)
Q2 20162($0.67)($0.57)($0.62)
Q3 20162($0.64)($0.63)($0.64)
Q4 20162($0.73)($0.71)($0.72)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ignyta (NASDAQ:RXDX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ignyta (NASDAQ:RXDX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/4/2016Alexander W CasdinDirectorBuy232,000$6.25$1,450,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2016Jacob ChackoCFOBuy10,000$5.64$56,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2016James L FreddoDirectorBuy3,000$5.39$16,170.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2016Jonathan E LimCEOBuy24,852$5.51$136,934.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2015Jacob ChackoCFOBuy1,500$12.00$18,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2015City Hill Venture Partners I,major shareholderBuy8,480$12.90$109,392.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Robert WildVPBuy1,200$16.35$19,620.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/20/2015Jonathan E LimCEOBuy20,000$9.01$180,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2015Alexander W CasdinDirectorBuy408,750$10.00$4,087,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2014Jacob ChackoCFOBuy1,598$6.46$10,323.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2014Jacob ChackoCFOBuy1,840$7.53$13,855.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2014Jonathan E LimCEOBuy5,000$7.60$38,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Ignyta (NASDAQ:RXDX)
DateHeadline
07/21/16 06:34 PMWhat's Ignyta Inc Downside After Today's Huge Decline? - Consumer Eagle
07/21/16 09:05 AMHow Analysts Rated Ignyta Inc (NASDAQ:RXDX) Last Week? - Consumer Eagle
07/16/16 05:40 PMShares Experiencing a Downtrend: Ignyta, Inc. (NASDAQ:RXDX) - TGP
07/16/16 05:40 PMArmistice Capital LLC Increased Ignyta INC (NASDAQ:RXDX) by $4.42 Million as Shares Declined - Consumer Eagle
07/16/16 05:40 PMShares Moving Down on the Week: Ignyta, Inc. (NASDAQ:RXDX) - Engelwood Daily
07/15/16 11:27 AMBroker Outlook For Ignyta, Inc. (RXDX) - Fiscal Standard
07/14/16 06:29 PMIgnyta Inc Realized Volatility Hits Extreme Level - CML News
07/14/16 09:51 AMIgnyta, Inc. (NASDAQ:RXDX) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/14/16 09:51 AMInsiders Increasing Positions in: Ignyta, Inc. (NASDAQ:RXDX) - Press Telegraph
07/14/16 09:51 AMHow Many Ignyta Inc (NASDAQ:RXDX)'s Analysts Are Bearish? - Consumer Eagle
07/11/16 06:09 PMWall Street Ratings and Target Price Views on Ignyta, Inc. (NASDAQ:RXDX) - Telanagana Press
07/10/16 05:28 PMIgnyta, Inc. (RXDX) Broker Price Targets For The Coming Week - Fiscal Standard
07/09/16 09:19 AMArmistice Capital LLC Increased Ignyta INC (NASDAQ:RXDX) by $4.42 Million as Shares Declined - Engelwood Daily
07/09/16 09:19 AMIgnyta, Inc. (RXDX) Current Analyst Ratings - Fiscal Standard
07/07/16 03:01 PMIgnyta to Present at 2016 Cantor Fitzgerald Healthcare Conference - [Business Wire] - Ignyta, Inc. , a biotechnology company focused on precision medicine in oncology, announced today that Jacob Chacko, M.D., its Chief Financial Officer, will make a presentation at the 2016 Cantor Fitzgerald Healthcare Conference on July 13, 2016, at 1:00 p.m.
07/07/16 09:00 AMStock Tracking Down This Month; Investor Alert on Ignyta, Inc. (NASDAQ:RXDX) - Engelwood Daily
07/07/16 09:00 AMCan Ignyta, Inc. (NASDAQ:RXDX) Improve on the Earnings Front? - Engelwood Daily
07/05/16 08:00 AMIgnyta Appoints Dr. Christian V. Kuhlen as General Counsel - [Business Wire] - Ignyta, Inc. , a biotechnology company focused on precision medicine in oncology, announced today that Dr. Christian V. Kuhlen has been appointed to serve as its General Counsel and Secretary, replacing Matt Onaitis.
07/04/16 05:23 PMIgnyta Inc Stock Price Increases Today - Engelwood Daily
07/02/16 05:47 PMIgnyta Secures $42 Million Term Loan Facility
07/01/16 06:15 PMTracking Stock Volatility for: Ignyta, Inc. (NASDAQ:RXDX) - Engelwood Daily
07/01/16 03:03 PMIGNYTA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligatio -
06/30/16 06:31 PMJP Morgan Initiates Coverage on Ignyta Inc to Overweight - Trade Calls
06/29/16 06:06 PMWere Analysts Bearish Ignyta Inc (NASDAQ:RXDX) This Week? - Engelwood Daily
06/28/16 11:01 AMCovering the Bases on Ignyta, Inc. (NASDAQ:RXDX): Where is the Stock Going? - Press Telegraph
06/27/16 06:09 PMNext Weeks Broker Price Targets For Ignyta, Inc. (RXDX) - Fiscal Standard
06/25/16 09:56 AMIgnyta Gets A Bullish Initiation From JPMorgan
06/25/16 09:56 AMJP Morgan recorded (NASDAQ:RXDX) Ignyta Inc, increasing its stock price target to $15 earlier today
06/24/16 06:19 PMCaesars Entertainment Corporation (NASDAQ:CZR) went up 3.46%: Ignyta, Inc. (NASDAQ:RXDX), ORBCOMM, Inc ... - KC Register
06/23/16 08:54 AMIgnyta, Inc. (NasdaqCM:RXDX) Stock Momentum Hits EXTREME Weakness - CML News
06/23/16 06:19 AMCoverage initiated on Ignyta by JP Morgan -
06/20/16 07:47 AMThis Weeks Broker Views For Ignyta, Inc. (RXDX) - Fiscal Standard
06/17/16 02:52 PMIgnyta's Entrectinib Data May Come By Year's End; Cantor Keeps Buy Rating, But Stock Slips 4% - Cantor analyst Mara Goldstein likes Ignyta Inc (NASDAQ: RXDX) shares for the opportunity provided by Entrectinib, which has multiple indications. As a result, she is confident that the drug could generate a bigger market than expected. The brokerage reiterated its rating of Buy and kept $18.00 as his price object on the shares of the company. The analyst expects final data for Ignyta's Drug study might come before the end of the current year. However, the brokerage pointed out that the regulator's "Pediatric Oncology Subcommittee will discuss investigator interest in exploring potential pediatric development plans for five drug candidates, including Entrectinib, on ...Full story available on Benzinga.com
06/15/16 03:02 PMIGNYTA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Securi -
06/08/16 06:46 PMIGNYTA INC. (NASDAQ:RXDX) Financial Condition Compared to S&P 500 - CML News
06/06/16 10:05 AMIgnyta (RXDX) Announces Encouraging Interim RXDX-105 Phase 1 Data
06/05/16 08:00 AMIgnyta Announces Interim Data from Phase 1 Clinical Trial of Investigational Precision Medicine RXDX-105 at ASCO 2016 - [Business Wire] - Ignyta, Inc. , a biotechnology company focused on precision medicine in oncology, today announced that interim results from the Phase 1 clinical trial of RXDX-105, the company’s orally available, small molecule multikinase inhibitor with potent activity against such targets as RET and BRAF, were presented at the 2016 Annual Meeting of the American Society of Clinical Oncology in Chicago .
06/04/16 09:12 AMInvestor's Healthcare Focused Stocks: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) , Ignyta, Inc. (NASDAQ:RXDX) - Is stories
06/02/16 06:42 PMIgnyta Inc (NASDAQ:RXDX)'s Company Shares Decreased 5.99% After Low Volatility - HNN - Ignyta Inc (NASDAQ:RXDX)'s Company Shares Decreased 5.99% After Low VolatilityHNNThe shares of Ignyta Inc (NASDAQ:RXDX) decreased by 5.99% in the last 20 days and lost 2.17% in the past 5 trading sessions. Ignyta Inc (NASDAQ:RXDX) shares opened at $6.75 in the last session and had intraday high of $6.88 and low of $6.55 for a ...Top Stock in Session: Ignyta, Inc. (NASDAQ:RXDX)The Postall 2 news articles »
06/02/16 06:42 PMIgnyta Inc (RXDX) Could Make You Big Time Money - Smarter Analyst - Smarter AnalystIgnyta Inc (RXDX) Could Make You Big Time MoneySmarter AnalystHaving done significant research and reviewing my AACR meeting notes I believe Ignyta (NASDAQ:RXDX) fits my model and is a huge steal at current levels. The personalized medicine company has a best-in-class cancer drug Entrectinib entering a pivotal ...
06/02/16 12:03 PMIgnyta, Inc. :RXDX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 2, 2016 -
05/30/16 10:15 PMIgnyta Inc (RXDX) Stock Rating Reaffirmed by Piper Jaffray - Let Me Know About This - Ignyta Inc (RXDX) Stock Rating Reaffirmed by Piper JaffrayLet Me Know About ThisIgnyta logo Ignyta Inc (NASDAQ:RXDX)'s stock had its “buy” rating reaffirmed by analysts at Piper Jaffray in a research note issued to investors on Sunday. They currently have a $32.00 price objective on the biopharmaceutical company's stock. Piper ...Ignyta, Inc. (RXDX) Broker Price Targets For The Coming WeekShare Trading NewsIgnyta Delaware (NASDAQ:RXDX) Shorted Shares Decreased By 37.35%Franklin Independentall 3 news articles »
05/28/16 07:02 PMArmistice Capital LLC Increased Ignyta INC (NASDAQ:RXDX) by $4.42 Million as Shares Declined - CCH Daily News - Armistice Capital LLC Increased Ignyta INC (NASDAQ:RXDX) by $4.42 Million as Shares DeclinedCCH Daily NewsArmistice Capital Llc increased its stake in Ignyta Inc (NASDAQ:RXDX) by 77.31% based on its latest 2016Q1 regulatory filing with the SEC. Armistice Capital Llc bought 736,000 shares as the company's stock declined 45.71% while stock markets rallied.and more »
05/26/16 03:00 PMIgnyta to Present at 2016 Jefferies Healthcare Conference - [Business Wire] - Ignyta, Inc. , a precision oncology biotechnology company, announced today that Jonathan Lim., M.D., its Chairman and Chief Executive Officer, will make a presentation at the 2016 Jefferies Healthcare Conference on June 8, 2016 at 11:30 a.m.
05/25/16 07:00 PMInsiders Are Gradually Buying Ignyta, Inc. (NASDAQ:RXDX) - Wall Street Hints and News - Insiders Are Gradually Buying Ignyta, Inc. (NASDAQ:RXDX)Wall Street Hints and NewsAccording to the latest SEC filings, insiders at Ignyta, Inc. (NASDAQ:RXDX) have increased their position in the stock by 1.77% over the past 6 months. Insiders now own 9.30% of total outstanding shares. There are both legal and illegal types of ...and more »
05/25/16 07:00 PMLatest Analyst Ratings For Ignyta, Inc. (RXDX) - Share Trading News - Latest Analyst Ratings For Ignyta, Inc. (RXDX)Share Trading NewsIgnyta, Inc. has a 50 day moving average of 7.17 and a 200 day moving average of 9.31. The stock's market capitalization is 287.35M, it has a 52-week low of 5.07 and a 52-week high of 19.40. The share price of the company (RXDX) was unchanged +0.00%, ...Were Analysts Bullish Ignyta Inc (NASDAQ:RXDX) This Week?Wall Street Hints and NewsIgnyta Announces RXDX-105 Phase 1 Data Presentation at the 2016 ASCO Annual MeetingBusiness Wire (press release)Ignyta Says RXDX-105 Phase 1 Data to Be Presented (NASDAQ:RXDX)Sonoran Weekly Reviewall 5 news articles »
05/25/16 07:00 PMIgnyta, Inc. (NASDAQ:RXDX) Impact Score At 50 - Investor Newswire - Ignyta, Inc. (NASDAQ:RXDX) Impact Score At 50Investor NewswireAlpha One explored various online articles released on Ignyta, Inc. (NASDAQ:RXDX), and it set a daily sentiment score of 0 on the company. The entity has an algorithm in place to know stock sentiment on the share after exploring the content issued on ...and more »
05/24/16 03:01 PM4:01 pm Ignyta to present updated data from Phase 1 clinical trial of RXDX-105 at ASCO -
05/24/16 03:00 PMIgnyta Announces RXDX-105 Phase 1 Data Presentation at the 2016 ASCO Annual Meeting - [Business Wire] - Ignyta, Inc. , a precision oncology biotechnology company, today announced the publication of an abstract for a poster session at the 2016 Annual Meeting of the American Society of Clinical Oncology in Chicago, Illinois.
05/23/16 07:06 PMBroker Outlook For The Week Ahead Ignyta, Inc. (RXDX) - Share Trading News - Broker Outlook For The Week Ahead Ignyta, Inc. (RXDX)Share Trading NewsThe most recently updated broker views and price targets issued for Ignyta, Inc. (RXDX) are below. 04/18/2016 – Broker: Jefferies Rating: buy New Target: 20 reiteration. 04/18/2016 – Broker: Piper Jaffray Rating: overweight New Target: 32 reiteration.

Social

About Ignyta

Ignyta logoIgnyta, Inc. is an oncology biotechnology company. The Company focuses on an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. Its Rx is focused on discovering, in licensing or acquiring, then developing and commercializing molecularly targeted therapies that, sequentially or in combination, are foundational for eradicating residual disease. Its Dx focuses on pairing the product candidates with biomarker-based companion diagnostics that are designed to identify, at the molecular level, the patients likely to benefit from the therapies. Its entrectinib is an orally bioavailable, small molecule tyrosine kinase inhibitor directed to the tropomyosin receptor kinase (Trk) family tyrosine kinase receptors (TrkA, TrkB and TrkC), ROS1 and anaplastic lymphoma kinase (ALK) proteins for the treatment of solid tumors. Its entrectinib is in Phase II/III of clinical development. Its taladegib is a small molecule and hedgehog or smoothened antagonist.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: RXDX
  • CUSIP:
Key Metrics:
  • Previous Close: $5.41
  • 50 Day Moving Average: $5.70
  • 200 Day Moving Average: $7.25
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $225.30M
  • Beta: 1.26
  • Current Year EPS Consensus Estimate: $-2.7 EPS
  • Next Year EPS Consensus Estimate: $-2.62 EPS
Additional Links:
Ignyta (NASDAQ:RXDX) Chart for Saturday, July, 23, 2016